## Does a Single CRISPR Infusion Durably Lower Lipids for a Year?

**The answer, in 15 patients at the highest dose tested: yes — with mean LDL reductions of 53%, triglyceride reductions of 48%, and no dose-limiting toxicity at 12 months.** Those numbers come from the phase 1a trial of CTX310, developed by CRISPR Therapeutics, published in *The New England Journal of Medicine* on August 28, 2026.

CTX310 delivers [CRISPR-Cas9](https://synbiointel.com/glossary/crispr-cas9) machinery — Cas9 mRNA paired with a guide RNA targeting ANGPTL3 — inside a lipid nanoparticle, editing hepatocytes in vivo to knock out the ANGPTL3 gene. The rationale is clean: naturally occurring loss-of-function variants in ANGPTL3 associate with low triglycerides, low LDL, and reduced atherosclerotic cardiovascular risk. CTX310 is attempting to reproduce that phenotype pharmacologically, in a single sitting.

The trial enrolled 15 adults with uncontrolled hypercholesterolaemia, moderate or severe hypertriglyceridaemia, or mixed dyslipidaemia — a difficult-to-treat population, most already on statins or ezetimibe, and 40% on PCSK9 inhibitors. Five dose levels were tested between 0.1 and 0.8 mg/kg.

Among the four participants who received the highest dose (0.8 mg/kg), one-year mean reductions were 79% for circulating ANGPTL3 (range 63–89%), 53% for LDL cholesterol, 48% for triglycerides, 37% for apolipoprotein B, and 72% for triglyceride-rich lipoprotein cholesterol. Those numbers are striking against a background of guideline-directed medical therapy. The study was led by co-first authors Luke Laffin at Cleveland Clinic and Stephen Nicholls at the Victorian Heart Institute, with Steven Nissen at Cleveland Clinic as senior author.

---

## What CTX310 Actually Does Inside the Liver

The delivery mechanism is a lipid nanoparticle carrying two RNA payloads: Cas9 mRNA and a guide RNA targeting hepatic ANGPTL3. After IV infusion, LNPs accumulate preferentially in hepatocytes — the same organ-targeting behavior that made mRNA COVID vaccines manufacturable at scale and that Intellia and Alnylam have leveraged for prior in vivo programs. The edit happens inside the body, distinguishing CTX310 from ex vivo [cell therapy](https://synbiointel.com/glossary/cell-therapy) approaches that require extracting, editing, and reinfusing a patient's own cells.

Because liver tissue turns over slowly, a successful hepatocyte edit is expected to persist for years or decades — which is the theoretical basis for the "one-and-done" framing. The one-year ANGPTL3 suppression data (79% mean reduction at the highest dose) supports that persistence hypothesis, at least within this follow-up window and this small cohort.

Beyond a transient aminotransferase elevation in one participant — reported previously at an earlier time point and not a new finding in this update — liver-function markers stayed within normal range through 12 months. That safety signal will require larger cohorts to fully interpret, but the one-year read-through without new events is meaningful.

---

## Where the Data Stops and the Hard Questions Begin

The phase 1a enrollment of 15 patients across five dose cohorts is too small to draw firm safety conclusions or to detect rare off-target editing events. Critically, the trial was not designed — and is not powered — to measure cardiovascular outcomes. The reduction in LDL, triglycerides, and apolipoprotein B are validated surrogate endpoints with strong precedent from statin and PCSK9 inhibitor trials, but translating surrogate improvements to hard outcomes (MI, stroke, cardiovascular death) will require a dedicated outcomes trial, likely enrolling thousands of patients over multiple years.

The highest-dose cohort contained just four participants. That is the group generating the headline 53% LDL figure. Dose-response consistency across all five arms, and durability beyond 12 months, remain to be established in phase 1b and phase 2 expansion cohorts.

There is also a reimbursement question that will eventually land on payers: a permanent or near-permanent genetic edit at a cost that is almost certainly in the six-to-seven-figure range per patient, versus lifetime PCSK9 inhibitor therapy that runs roughly $6,000–$14,000 per year depending on rebate structure. The pharmacoeconomic model works only if durability extends well beyond the current one-year window, and if the patient population can be stratified tightly enough to justify the upfront cost. None of those figures come from the NEJM publication — they represent the commercial reality that will determine whether CTX310's Phase 3 path is funded.

---

## Industry Trajectory: In Vivo Editing Enters the Cardiometabolic Arena

The publication lands at a moment when in vivo [CRISPR-Cas9](https://synbiointel.com/glossary/crispr-cas9) is accumulating a track record in the liver. Intellia Therapeutics has demonstrated in vivo TTR knockdown with NTLA-2001 in transthyretin amyloidosis. Verve Therapeutics has run VERVE-101, a [base editing](https://synbiointel.com/glossary/base-editing) approach also targeting PCSK9 hepatically. CTX310 occupies the ANGPTL3 node — a target with strong human genetics validation and a different mechanism from PCSK9 inhibition, potentially additive in patients with residual risk on maximum tolerated statin plus PCSK9 inhibitor.

That the patient population in this trial already included PCSK9 inhibitor users — and still showed 53% LDL reductions from baseline — is the data point that most distinguishes CTX310 from incremental lipid-lowering iterations. If the trajectory holds in larger cohorts, it positions CRISPR Therapeutics to compete not just with incumbent biologics but with the emerging RNA interference players (inclisiran from Novartis already on market) in the lipid management space.

For the broader synthetic biology and gene therapy sector, CTX310's one-year data adds clinical credibility to the LNP-delivered in vivo editing platform — the same LNP chemistry that underpins multiple next-generation therapeutic programs. Each durable efficacy and safety readout de-risks not just CRISPR Therapeutics' pipeline but the delivery modality itself.

---

## Key Takeaways

- **53% mean LDL reduction and 48% triglyceride reduction at one year** in the highest-dose cohort (4 patients, 0.8 mg/kg) of CRISPR Therapeutics' CTX310 phase 1a trial
- **79% mean ANGPTL3 suppression** (range 63–89%) at the highest dose — consistent with durable hepatocyte editing via lipid nanoparticle delivery
- **No dose-limiting toxicity and no new treatment-related adverse events** at 12 months across all 15 participants; one previously reported transient aminotransferase elevation did not recur
- **Patient population included PCSK9 inhibitor users** (40%), making the residual LDL reduction clinically meaningful in a real-world hard-to-treat context
- **Cardiovascular outcomes remain untested** — this is a surrogate-endpoint phase 1a; the trial was not powered or designed for hard endpoint measurement
- **Published in NEJM August 28, 2026**, led by Luke Laffin and Stephen Nicholls (co-first authors) and Steven Nissen (senior author)
- The LNP-delivered in vivo CRISPR edit approach, if durable, positions single-dose therapy as a structural competitor to lifelong PCSK9 inhibitor or RNA interference dosing schedules

---

## Frequently Asked Questions

**What is CTX310 and how does it work?**
CTX310 is an in vivo [CRISPR-Cas9](https://synbiointel.com/glossary/crispr-cas9) gene-editing therapy developed by CRISPR Therapeutics. It delivers Cas9 mRNA and a guide RNA targeting ANGPTL3 inside a lipid nanoparticle, which preferentially accumulates in hepatocytes after IV infusion. The edit knocks out ANGPTL3 in liver cells, mimicking naturally occurring loss-of-function variants associated with low LDL and triglycerides.

**What lipid reductions did CTX310 achieve at one year?**
In the four participants receiving the highest tested dose (0.8 mg/kg), mean reductions at 12 months were 53% for LDL cholesterol, 48% for triglycerides, 79% for ANGPTL3, 37% for apolipoprotein B, and 72% for triglyceride-rich lipoprotein cholesterol, according to data published in the New England Journal of Medicine on August 28, 2026.

**Is CTX310 safe based on the phase 1a data?**
No dose-limiting toxicity and no new treatment-related adverse events were reported at one year across all 15 participants. One transient aminotransferase elevation had been reported earlier in the trial but did not persist. These are early-stage safety data from a small cohort — larger trials are required for a full adverse event profile.

**How does CTX310 compare to PCSK9 inhibitors or inclisiran?**
CTX310 targets ANGPTL3 rather than PCSK9, meaning it operates by a distinct mechanism and could be additive to PCSK9 inhibition. Notably, 40% of trial participants were already on PCSK9 inhibitors and still showed substantial LDL reductions. Unlike biologic PCSK9 inhibitors (dosed every 2–4 weeks) or inclisiran (twice yearly), CTX310 is designed as a single administration — though long-term durability beyond 12 months is not yet established.

**What are the next steps for CTX310 in clinical development?**
Phase 1a results support dose selection for expanded cohorts. Phase 1b and Phase 2 trials will need to enroll larger patient populations to confirm durability, establish a broader safety profile, and characterize off-target editing. A cardiovascular outcomes trial would eventually be required for regulatory approval in a primary or secondary prevention indication.